SCHEMBL3034837

SCHEMBL3034837

CCC(=O)N(CCCCN1CCN(c2ccccc2)CC1)C1CCc2ccc(OC)cc2C1

nearest known ligand 0.58

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 11/20 0.58
DRD3 P35462 11/20 0.58
MCHR1 Q99705 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3032783 0.94 DRD2 (0.56) DRD2DRD3
SCHEMBL3030571 0.84 DRD2 (0.77) DRD2DRD3
SCHEMBL3289815 0.82 DRD2 (0.66) DRD2DRD3
SCHEMBL3290106 0.82 DRD2 (0.66) DRD2DRD3
SCHEMBL3030507 0.81 DRD2 (0.76) DRD2DRD3
SCHEMBL3022282 0.81 DRD2 (0.78) DRD2DRD3
SCHEMBL3033284 0.81 DRD2 (0.77) DRD2DRD3
SCHEMBL11323761 0.80 DRD2 (0.56) DRD2DRD3MCHR1
SCHEMBL3029994 0.80 DRD2 (0.76) DRD2DRD3
SCHEMBL3033679 0.76 DRD2 (0.76) DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8227604-B2 Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity WAYNE STATE UNIVERSITY (US) 2012-07-24 US disclosed
US-20100210663-A1 Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity WAYNE STATE UNIVERSITY (US) 2010-08-19 US disclosed
US-7723519-B2 Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity WAYNE STATE UNIVERSITY (US) 2010-05-25 US disclosed
US-20060020132-A1 Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity WAYNE STATE UNIVERSITY (US) 2006-01-26 US disclosed
US-6982332-B2 Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity WAYNE STATE UNIVERSITY (US) 2006-01-03 US disclosed
US-20030195219-A1 Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity WAYNE STATE UNIVERSITY 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195219-A1 Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity HTR3A, HTR3C, HTR2C DRD2 5/4885DRD3 7/4885MCHR1 279/4885
US-20100210663-A1 Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity HTR3A, HTR3C, HTR2C DRD2 5/4885DRD3 7/4885MCHR1 282/4885
US-20060020132-A1 Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity HTR3A, DRD3, DRD2 DRD2 3/4885DRD3 2/4885MCHR1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.